Compare Angi Inc (ANGI) vs 10X Genomics Inc (TXG) Price & Performance

ANGI trades at $4.83, up 7.57% today, but faces significant headwinds with revenue declining from $1.9B in 2022 to an estimated $993M in 2026. The company reported a substantial Q2 2026 earnings miss with EPS of -$5.70 versus $0.13 expected, reflecting ongoing challenges in user retention and platform engagement. Technical indicators show bearish momentum with the stock trading near key support levels, while valuation metrics appear attractive with P/E of 14.81 and P/S of 0.18.

Despite low valuations, ANGI's deteriorating fundamentals and negative investor sentiment create substantial risk. The company faces a negative earnings cycle with accelerating pro user churn and declining leads. While analyst consensus targets $7.00 (45% upside), ongoing fraud investigations and competitive pressures suggest cautious approach warranted until clear turnaround catalysts emerge.

TXG trades at $58.15, down 0.5% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q2 2026 earnings beating estimates, with revenue of $151 million and a loss per share of $0.14 versus an expected $0.24 loss. Gross margin improved to 70.03%, and cash flow from operations strengthened to $136 million in 2025. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook is mixed: analyst consensus is a Hold with a $48.38 price target below current levels, indicating caution despite recent earnings beats. Risks include persistent net losses, high valuation multiples like a P/S of 11.95, and competitive pressures in life sciences. Institutional activity shows mixed signals, with some firms increasing stakes while others reduce holdings.